Literature DB >> 15831828

Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Seema Mattoo1, James D Cherry.   

Abstract

Bordetella respiratory infections are common in people (B. pertussis) and in animals (B. bronchiseptica). During the last two decades, much has been learned about the virulence determinants, pathogenesis, and immunity of Bordetella. Clinically, the full spectrum of disease due to B. pertussis infection is now understood, and infections in adolescents and adults are recognized as the reservoir for cyclic outbreaks of disease. DTaP vaccines, which are less reactogenic than DTP vaccines, are now in general use in many developed countries, and it is expected that the expansion of their use to adolescents and adults will have a significant impact on reducing pertussis and perhaps decrease the circulation of B. pertussis. Future studies should seek to determine the cause of the unique cough which is associated with Bordetella respiratory infections. It is also hoped that data gathered from molecular Bordetella research will lead to a new generation of DTaP vaccines which provide greater efficacy than is provided by today's vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831828      PMCID: PMC1082800          DOI: 10.1128/CMR.18.2.326-382.2005

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  721 in total

1.  The Phases of Haemophilus pertussis.

Authors:  P H Leslie; A D Gardner
Journal:  J Hyg (Lond)       Date:  1931-07

2.  Interaction of the Bordetella pertussis filamentous hemagglutinin with heparin.

Authors:  F D Menozzi; C Gantiez; C Locht
Journal:  FEMS Microbiol Lett       Date:  1991-02       Impact factor: 2.742

3.  Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections.

Authors:  S A Halperin; R Bortolussi; J M Langley; B Miller; B J Eastwood
Journal:  Pediatrics       Date:  1997-07       Impact factor: 7.124

4.  A study of dogs with kennel cough.

Authors:  I A McCandlish; H Thompson; H J Cornwell; N G Wright
Journal:  Vet Rec       Date:  1978-04-08       Impact factor: 2.695

5.  Summary of notifiable diseases, United States 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-10-25       Impact factor: 17.586

6.  Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin.

Authors:  G J Spangrude; F Sacchi; H R Hill; D E Van Epps; R A Daynes
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

7.  DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose.

Authors:  L J Baraff; C L Cody; J D Cherry
Journal:  Pediatrics       Date:  1984-01       Impact factor: 7.124

8.  The non-specific enhancement of allergy. I. In vivo effects of Bordetella pertussis vaccine on IgE synthesis.

Authors:  R Pauwels; M Van der Straeten; B Platteau; H Bazin
Journal:  Allergy       Date:  1983-05       Impact factor: 13.146

9.  Further experience of reactions, especially of a cerebral nature, in conjunction with triple vaccination: a study based on vaccinations in Sweden 1959-65.

Authors:  J Ström
Journal:  Br Med J       Date:  1967-11-11

10.  Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences.

Authors:  A van der Zee; F Mooi; J Van Embden; J Musser
Journal:  J Bacteriol       Date:  1997-11       Impact factor: 3.490

View more
  378 in total

1.  Seroprevalence of pertussis among Danish patients with cough of unknown etiology.

Authors:  Tine Dalby; Zitta B Harboe; Karen Angeliki Krogfelt
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

2.  Bordetella bronchiseptica in a paediatric cystic fibrosis patient: possible transmission from a household cat.

Authors:  K B Register; N Sukumar; E L Palavecino; B K Rubin; R Deora
Journal:  Zoonoses Public Health       Date:  2012-01-02       Impact factor: 2.702

3.  Contribution of Bordetella filamentous hemagglutinin and adenylate cyclase toxin to suppression and evasion of interleukin-17-mediated inflammation.

Authors:  Michael W Henderson; Carol S Inatsuka; Amanda J Sheets; Corinne L Williams; David J Benaron; Gina M Donato; Mary C Gray; Erik L Hewlett; Peggy A Cotter
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

Review 4.  Towards improved accuracy of Bordetella pertussis nucleic acid amplification tests.

Authors:  Michael Loeffelholz
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

5.  Antibody response from whole-cell pertussis vaccine immunized Brazilian children against different strains of Bordetella pertussis.

Authors:  Alexandre Pereira; Aparecida S Pietro Pereira; Célio Lopes Silva; Gutemberg de Melo Rocha; Ivo Lebrun; Osvaldo A Sant'Anna; Denise V Tambourgi
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

Review 6.  Bordetella pertussis transmission.

Authors:  Elizabeth A Trainor; Tracy L Nicholson; Tod J Merkel
Journal:  Pathog Dis       Date:  2015-09-14       Impact factor: 3.166

Review 7.  What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.

Authors:  Shelly Bolotin; Eric T Harvill; Natasha S Crowcroft
Journal:  Pathog Dis       Date:  2015-08-06       Impact factor: 3.166

8.  Maternal and neonatal vaccination protects newborn baboons from pertussis infection.

Authors:  Jason M Warfel; James F Papin; Roman F Wolf; Lindsey I Zimmerman; Tod J Merkel
Journal:  J Infect Dis       Date:  2014-02-12       Impact factor: 5.226

Review 9.  Toward a mechanism-based in vitro safety test for pertussis toxin.

Authors:  Stefan F C Vaessen; Martijn W P Bruysters; Rob J Vandebriel; Saertje Verkoeijen; Rogier Bos; Cyrille A M Krul; Arnoud M Akkermans
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

10.  Expression of BfrH, a putative siderophore receptor of Bordetella bronchiseptica, is regulated by iron, Fur1, and the extracellular function sigma factor EcfI.

Authors:  Jonathan M Burgos; Natalie D King-Lyons; Terry D Connell
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.